Tru Niagen Nicotinamide Riboside (NR) 300mg Review

It matters, and we label it plainly so you can decide. Nicotinamide riboside (NR) and NMN are both NAD+ precursors; NR sits one step further back in the same pathway your body uses to make NAD+. If you came specifically for NMN, this isn't that molecule. But if your actual goal is raising NAD+ from a precursor you can trust and reliably buy, NR is the better-evidenced, more stable choice — which is exactly why we include it as the lead alternative. Tru Niagen is NR done well; it is not a substitute for NMN if NMN itself is the requirement.

Three reasons, all verifiable. First, evidence: the patented Niagen NR raw material carries an unusually deep clinical-research base for this category — multiple human trials (Martens 2018, Elhassan 2019) show NR reliably raises NAD+. Second, testing: the brand states each batch is third-party tested by ISO/IEC-accredited labs, a genuine independent-lab claim. Third, availability: because NR is not subject to the FDA's NMN exclusion, it stays reliably in stock rather than vanishing or rotating ASINs. For trust and dependability, nothing else in the lineup matches it.

Honest answer: it reliably raises NAD+, and the functional benefits are less certain. NR's human trials consistently show it elevates NAD+ metabolism (Martens 2018), but Elhassan 2019 — which raised the muscle NAD+ metabolome in older men — found no change in mitochondrial bioenergetics or measured physical performance. So NR is the best-evidenced NAD+ booster for moving the biomarker, while the leap from 'NAD+ up' to 'I feel or function better' remains the open question across this whole category, NMN included. Buy it for the NAD+-raising and the trust, not for a guaranteed felt effect.

It's the premium end. At roughly $1.33 per once-daily 300 mg capsule, the 30-count is a one-month supply, so it costs more per month than the commodity single-ingredient NMN options like Double Wood (#7) or Partiqlar (#4). What you're paying for is the patented Niagen raw material, the clinical-research base and ISO/IEC-accredited testing — a trust premium, not a volume discount. If cost-per-gram is your priority over the NR evidence and stability, the budget NMN picks are cheaper; if trust and availability lead, the premium is the point.

That's its structural advantage. Because nicotinamide riboside is not affected by the FDA's late-2022 NMN-exclusion stance, Tru Niagen lists far more stably on Amazon than NMN products that get relabeled, recategorized or rotated to new ASINs. It's vegetarian and free of gluten, nuts and caffeine, and it's a once-daily capsule. For a buyer who's been burned by an NMN listing disappearing, the reliable supply is a real, practical reason to choose NR here.

1. [1] Martens 2018 PMID 29599478 — Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. A randomized, double-blind, placebo-controlled crossover trial showed 6 weeks of NR (1,000 mg/day) was well tolerated and effectively raised NAD+ metabolism in healthy middle-aged and older adults. The key human evidence for NR — the regulatorily-stable, best-studied NAD+ precursor Tru Niagen is built on.
2. [2] Elhassan 2019 PMID 31412242 — Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. 21 days of NR (1,000 mg/day) in aged men raised the muscle NAD+ metabolome and produced anti-inflammatory signatures, but did NOT change mitochondrial bioenergetics or physical performance. The honest illustration of the gap between raising NAD+ and producing a functional benefit — the core caution applied to Tru Niagen and the whole category.
3. [3] Yoshino 2021 PMID 33888596 — Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Included for honest comparison: this is the headline NMN trial (250 mg/day improved insulin sensitivity). It is NMN evidence, not NR — relevant here because Tru Niagen is the NR alternative to the NMN products, and buyers should see both precursors' evidence side by side.